Cargando…
Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients
Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we r...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984282/ https://www.ncbi.nlm.nih.gov/pubmed/35399933 http://dx.doi.org/10.3389/fendo.2022.794512 |
_version_ | 1784682151829045248 |
---|---|
author | Papadopoulos, Sotirios Koulouris, Pantelis Royer-Chardon, Claire Tsoumakidou, Georgia Dolcan, Ana Cherix, Stephane Matter, Maurice Omoumi, Patrick Digklia, Antonia |
author_facet | Papadopoulos, Sotirios Koulouris, Pantelis Royer-Chardon, Claire Tsoumakidou, Georgia Dolcan, Ana Cherix, Stephane Matter, Maurice Omoumi, Patrick Digklia, Antonia |
author_sort | Papadopoulos, Sotirios |
collection | PubMed |
description | Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we report two cases of patients with desmoid tumors, treated with pazopanib and imatinib, who developed reactional lymphadenopathy. As this side effect is presented as a newly formed mass, it can result in new diagnostic questions and added imaging tests and can even lead to discontinuation of the treatment. This report may help the clinicians facing similar problems adopt a “watch and wait” approach. |
format | Online Article Text |
id | pubmed-8984282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89842822022-04-07 Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients Papadopoulos, Sotirios Koulouris, Pantelis Royer-Chardon, Claire Tsoumakidou, Georgia Dolcan, Ana Cherix, Stephane Matter, Maurice Omoumi, Patrick Digklia, Antonia Front Endocrinol (Lausanne) Endocrinology Tyrosine kinase inhibitors (TKIs) are nowadays a valuable treatment of desmoid tumors, a rare mesenchymal neoplasm. Although many side effects of imatinib and pazopanib, commonly or rarely occurring, have been described, reactional lymphadenopathy has not yet been reported. In this publication, we report two cases of patients with desmoid tumors, treated with pazopanib and imatinib, who developed reactional lymphadenopathy. As this side effect is presented as a newly formed mass, it can result in new diagnostic questions and added imaging tests and can even lead to discontinuation of the treatment. This report may help the clinicians facing similar problems adopt a “watch and wait” approach. Frontiers Media S.A. 2022-03-23 /pmc/articles/PMC8984282/ /pubmed/35399933 http://dx.doi.org/10.3389/fendo.2022.794512 Text en Copyright © 2022 Papadopoulos, Koulouris, Royer-Chardon, Tsoumakidou, Dolcan, Cherix, Matter, Omoumi and Digklia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Papadopoulos, Sotirios Koulouris, Pantelis Royer-Chardon, Claire Tsoumakidou, Georgia Dolcan, Ana Cherix, Stephane Matter, Maurice Omoumi, Patrick Digklia, Antonia Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients |
title | Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients |
title_full | Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients |
title_fullStr | Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients |
title_full_unstemmed | Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients |
title_short | Case Report: Tyrosine Kinase Inhibitors Induced Lymphadenopathy in Desmoid Tumor Patients |
title_sort | case report: tyrosine kinase inhibitors induced lymphadenopathy in desmoid tumor patients |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984282/ https://www.ncbi.nlm.nih.gov/pubmed/35399933 http://dx.doi.org/10.3389/fendo.2022.794512 |
work_keys_str_mv | AT papadopoulossotirios casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients AT koulourispantelis casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients AT royerchardonclaire casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients AT tsoumakidougeorgia casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients AT dolcanana casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients AT cherixstephane casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients AT mattermaurice casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients AT omoumipatrick casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients AT digkliaantonia casereporttyrosinekinaseinhibitorsinducedlymphadenopathyindesmoidtumorpatients |